Case-Finding and Treatment Effects in COPD: Secondary Analysis of an Interdisciplinary Intervention Trial
Kate Petrie,Michael Abramson,Johnson George
DOI: https://doi.org/10.2147/copd.s436690
2024-02-15
International Journal of COPD
Abstract:Kate Petrie, 1 Michael J Abramson, 2 Johnson George 1, 2 1 Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia; 2 School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia Correspondence: Johnson George, Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia, Email Background: US Preventive Services Taskforce recommends against screening for COPD in asymptomatic adults due to limited evidence on the efficacy of treatments for this population. However, global and Australian guidelines recommend a case-finding approach where those with symptoms and/or risk factors, including smoking, are screened. This study aims to explore patient characteristics by time of COPD diagnosis and the effectiveness of early treatment in those with or without symptoms. Methods: Secondary analysis of a randomised controlled trial that included those with a pre-existing (n=130) or new diagnosis (n=142) of COPD. Those randomised to the intervention arm received an interdisciplinary intervention of smoking cessation support, home medicines review and home-based pulmonary rehabilitation, while controls received usual care. The primary outcome was health-related quality of life (HR-QoL) measured using St George's Respiratory Questionnaire. To estimate the impact of early treatment, we compared the effectiveness of treatment versus control at 6- and 12-months for the new versus pre-existing diagnosis groups, and those symptomatic versus asymptomatic or minimally symptomatic based on COPD Assessment Test score. Results: Approximately half of those newly diagnosed with COPD were already symptomatic. Early treatment in those diagnosed via case-finding had a positive non-significant impact on HR-QoL. The size of the treatment effects generally favoured the pre-existing diagnosis group when compared to case-finding and favoured those symptomatic when compared to those asymptomatic. Conclusion: Despite useful insights into the impacts of case-finding and early treatments, this study, like most others, was not sufficiently powered. Further larger studies or combining sub-groups across studies are required. Keywords: RCT, screening, interdisciplinary, COPD Despite the significant morbidity and mortality associated with chronic obstructive pulmonary disease (COPD), few trials have investigated the impact of screening. The US Preventive Services Taskforce (USPSTF) updated (May 2022) their COPD screening guidance (following a systematic review) and recommended against screening in asymptomatic adults. 1 This recommendation was based on the current lack of supportive evidence for intervention(s) in those who did not recognise their respiratory symptoms at a level that would prompt them to seek consultation with a doctor. 1,2 The USPSTF specifically stated, "do not screen for COPD in patients with no symptoms", but this "does not apply to populations at very high risk for COPD, such as persons with α 1 -antitrypsin deficiency or workers exposed to certain toxins at their work" as these high-risk populations were not specifically included in the review. 1 The recommendation in support of screening did not extend to those with a history of smoking and, therefore, the USPSTF recommended that those with a history of smoking should be symptomatic prior to screening for COPD. 1 An earlier diagnosis of COPD could reduce the burden of COPD through earlier access to pharmacological and non-pharmacological treatments. 3 There is also an increasing focus on a "pre-COPD" population who are at-risk of COPD but may have risk factor(s) with preserved lung function. 3 Therefore, despite the USPSTF recommendations, the Global initiative for Obstructive Lung Disease (GOLD) and Australian COPD-X guidelines recommend a case-finding approach (targeted screening) where those at risk of COPD, including those with a smoking history, are screened using a COPD screening device, irrespective of symptoms. 4,5 The diagnosis of COPD itself may evoke some response from a patient. 6,7 To the best of our knowledge, there has been no trial that has specifically aimed to investigate the impact of COPD screening (or case-finding) on outcomes including respiratory symptoms and behavioural changes such as smoking cessation. However, a Cochrane review investigated the potential impact of biomedical risk assessment(s), including spirometry, to aid smoking cessation. 8 This review found little supportive evidence for biomedical risk assessment as smoking cessation aids, with spirometry showing some positive benefit once high risk of bias studie -Abstract Truncated-
respiratory system